

In the Claims:

1. – 20. (Cancelled)

21. (Currently amended) A method for screening and identifying a compound which inhibits atherosclerosis or restenosis ~~comprising the use of PDE4 as a target~~, wherein said method comprises:

- a) measuring phosphodiesterase activity of a PDE4 target,
- b) administering a compound suspected to be an activator or inhibitor of PDE4 to the PDE4 target; and
- c) measuring the activation or inhibition of the phosphodiesterase activity of PDE4 by the compound,

wherein inhibition of the phosphodiesterase activity of PDE4 would identify a compound which inhibits atherosclerosis or restenosis; and wherein the PDE4 is selected from the group consisting of PDE4D, PDE4D5 and PDE4D7.

22. (Canceled)

23. (Currently presented) The method of claim 21 22, wherein the PDE4 is PDE4D7.

24. – 26. (Canceled)

27. (Withdrawn) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to a non-human animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.

28. (Withdrawn) The process of claim 27, wherein said PDE4 is PDE4D.

29. (Withdrawn) The process of claim 28 wherein the PDE4D is selected from the group consisting of PDE4D5 or PDE4D7.

30. (Withdrawn) The process of claim 28 wherein the PDE4D is PDE4D7.

31. (Withdrawn) The compound of claim 21.

32. (Withdrawn) The compound of claim 25.

33. (Withdrawn) The compound of claim 27.

34. (Withdrawn) A pharmaceutical composition comprising the compound of claim 32 and a pharmaceutically acceptable isomer.

35. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 34 to a subject having PAOD.

36. (Withdrawn) A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable isomer.

37. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 36 to a subject suffering from atherosclerosis or restenosis.